CD4 aptamer-engineered cell platforms enhance anti-tumor immunity in triple-negative breast cancer
Cell Biomaterials · 2026-01 · 2 (1) · 100218
DOI: 10.1016/j.celbio.2025.100218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biomaterials, 2026-01. Verfasst von Heming Tang und 9 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Key Research and Development Program of Zhejiang Province, Zhejiang Province Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Key Research and Development Program of Zhejiang Province
- Zhejiang Province Natural Science Foundation
- National Natural Science Foundation of China
- Chinese Academy of Sciences
Zitieren
APA
Tang, H., Xiong, Y., Gan, S., Fei, L., Guo, L., Zhang, K., Li, H., Fu, T., Wu, Q., & Tan, W. (2026). CD4 aptamer-engineered cell platforms enhance anti-tumor immunity in triple-negative breast cancer. Cell Biomaterials, 2(1), 100218. https://doi.org/10.1016/j.celbio.2025.100218
Vancouver
Tang H, Xiong Y, Gan S, Fei L, Guo L, Zhang K, et al. CD4 aptamer-engineered cell platforms enhance anti-tumor immunity in triple-negative breast cancer. Cell Biomaterials. 2026;2(1):100218. doi:10.1016/j.celbio.2025.100218
BibTeX
@article{Tang2026,
author = {Tang, Heming and Xiong, Yalin and Gan, Shaoju and Fei, Liyan and Guo, Lu and Zhang, Kejing and Li, Haowen and Fu, Ting and Wu, Qin and Tan, Weihong},
title = {CD4 aptamer-engineered cell platforms enhance anti-tumor immunity in triple-negative breast cancer},
journal = {Cell Biomaterials},
year = {2026},
volume = {2},
number = {1},
pages = {100218},
doi = {10.1016/j.celbio.2025.100218}
}
EUVIMED